Gain Therapeutics Inc at B Riley Neuro & Ophthalmology Conference (Virtual) Transcript
Good afternoon, and good morning to folks on the West Coast. And thanks for joining us for our next company fireside chat with Gain Therapeutics' Chief Operating Officer, Matthias Alder.
Thank you for taking out time of your busy schedule. I know you have a lot going on at Gain. Maybe at the highest level, talk a little bit about the company overview, pipeline, how should we think about some of the milestones in the next several years.
Absolutely. Thank you, Mayank, and thanks for the opportunity to talk here this afternoon, or morning on the West Coast.
So just to give you -- for people who are not familiar with Gain, give you a bit of a background about the company first. So we are a preclinical-stage company, biotech company. We were established in 2017.
And the core of the company is based around a physics-based computational drug-discovery platform that was developed by our Chief Technology Officer, Xavier Barril, at the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
